RCKT
ROCKET PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 18 ▼ 3 insiders sell $28.4K at $3.34
- Mar 28 FDA decision: PDUFA: RCKT, KRESLADI in severe leukocyte adhesion deficie…
- May 7 to May 21 ▼ 4 days of insider sells: $272.0K by 4 insiders, avg $3.28
- Aug 3 ▲ Rocket Pharmaceuticals announced a positive clinical safety update f…
- Aug 10 ▲ Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M (…
- Aug 11 to Aug 18 ▼ 3 days of insider sells: $176.0K by 4 insiders, avg $3.48
- Sep 11 ▼ 1 insider sell $256.5K at $3.40
- Sep 15 ▲ Rocket Pharmaceuticals announced FDA alignment on the path to comple…
- Sep 16 ▲ Needham upgrades
- Oct 6 ▲ Rocket Pharmaceuticals entered into a $150M senior secured credit fa…
- Oct 8 ▲ Goldman Sachs upgrades
- Nov 5 to Nov 9 ▼ 2 days of insider sells: $139.2K by 2 insiders, avg $2.39
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $872.0K.
- InstitutionsMIXED
Q3 2026: 16 added (0 new), 20 trimmed or exited.
- AnalystsBULLISH
12 of 20 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −0.2% to 16.24M shares. 9.1 days to cover, ≈14.8% of shares.
- TrendRANGE
19% below its 50-day average. New closing low $2.16 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $34.6M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $4.5M |
| MORGAN STANLEY | ADD | $3.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | NEAR_EXIT | $3.8M |
| Aberdeen Group plc | DOUBLED | $3.1M |
| FMR LLC | DOUBLED | $2.7M |
| JPMORGAN CHASE & CO | TRIM | $2.0M |
| Jump Financial, LLC | TRIM | $1.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is below the lowest target. Median implies +363%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 8, 2026 | Goldman Sachs UPGRADE | Neutral |
| Oct 7, 2026 | Leerink Partners MAINTAIN | Market Perform |
| Oct 7, 2026 | Wedbush REITERATE | Outperform |
| Oct 7, 2026 | Chardan Capital MAINTAIN | Buy |
| Sep 16, 2026 | Wedbush REITERATE | Outperform |
| Sep 16, 2026 | Needham UPGRADE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Chaudhuri Sarbani See Remarks Nov 9, 2026 | SELL | $11.3K |
Wilson Martin General Counsel Nov 5, 2026 | SELL | $127.8K |
Wilson Martin General Counsel Sep 11, 2026 | SELL | $256.5K |
Wilson Martin General Counsel Aug 18, 2026 | SELL | $2.1K |
Shah Gaurav CEO Aug 18, 2026 | SELL | $7.8K |
Shah Gaurav CEO Aug 13, 2026 | SELL | $9.6K |
Wilson Martin General Counsel Aug 13, 2026 | SELL | $11.8K |
Stevens Christopher James Chief Operating Officer Aug 11, 2026 | SELL | $128.3K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 5 bullish · 1 bearish · 15 neutral- NEUTRAL 144Nov 13, 2026
Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent…
The filing is a routine intent-to-sell notice for a small number of shares, likely for tax withholding on equity vesting. No material impact on stock price expected. Monitor future Form 4 filings to…
- NEUTRAL 144Nov 13, 2026
Officer Martin Wilson filed Form 144 notice to sell 4,087 shares of Rocket Pharmaceuticals, valued…
The sale is a routine tax-withholding transaction tied to equity vesting. No material insider sentiment signal; monitor for any larger unplanned sales in future Form 4 filings.
- NEUTRAL CLUSTERNov 12, 2026
Two insiders at Rocket Pharmaceuticals sold a combined $139K in open-market sales within days of…
The sales are trivial in size relative to market cap and involve the General Counsel and a non-C-suite insider. No material bearish signal. Monitor next insider cluster for larger dollar amounts or…
- NEUTRAL 8-KNov 12, 2026
Rocket Pharmaceuticals reported Q3 2026 financial results: net loss of $49.2 million ($0.43 per…
The FDA alignment on the Danon disease pivotal trial is the most significant catalyst. Monitor enrollment progress toward the mid-2027 dosing completion target and any interim safety/efficacy…
All RCKT filing & press-release reports (21)
- 144 reportNov 13, 2026
- 144 reportNov 13, 2026
- CLUSTER reportNov 12, 2026
- 8-K reportNov 12, 2026
- 144 reportNov 9, 2026
- 144 reportNov 9, 2026
- 144 reportNov 5, 2026
- SC 13G/A reportOct 30, 2026
- 8-K reportOct 6, 2026
- 8-K reportSep 15, 2026
- CLUSTER reportAug 20, 2026
- CLUSTER reportAug 17, 2026
- CLUSTER reportAug 13, 2026
- 8-K reportAug 10, 2026
- 8-K reportAug 3, 2026
- 8-K reportJun 30, 2026
- 8-K reportJun 12, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 7, 2026
- EFFECT reportMar 11, 2026
- S-3 reportMar 2, 2026